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The	  brain	  processes	   sensory	   information	   in	   neuronal	   networks	   that	   are	   shaped	  by	   experience,	   particularly	  
during	   early	   life,	   to	   optimally	   represent	   the	   internal	   and	   external	  milieu.	   	   Recent	   surprising	   findings	   have	  
revealed	  that	  antidepressant	  drugs	  reactivate	  a	  window	  of	  juvenile-­‐like	  plasticity	  in	  the	  adult	  cortex.	  	  When	  
antidepressant-­‐induced	   plasticity	   was	   combined	   with	   appropriate	   rehabilitation,	   it	   brought	   about	   a	  
functional	   recovery	   of	   abnormally	   wired	   neuronal	   networks.	   	   These	   observations	   suggest	   that	  
antidepressants	   act	   permissively	   to	   facilitate	   environmental	   influence	  on	   neuronal	   network	   reorganization	  
and	  so	  provide	  a	  plausible	  neurobiological	  explanation	  for	  the	  enhanced	  effect	  of	  combining	  antidepressant	  
treatment	  with	  psychotherapy.	  The	  results	  emphasize	  that	  pharmacological	  and	  psychological	  treatments	  of	  
mood	   disorders	   are	   closely	   entwined:	   The	   effect	   of	   antidepressant-­‐induced	   plasticity	   is	   facilitated	   by	  
rehabilitation,	  such	  as	  psychotherapy,	  that	  guides	  the	  plastic	  networks,	  and	  psychotherapy	  benefits	  from	  the	  
enhanced	   plasticity	   provided	   by	   the	   drug	   treatment.	   	   Optimized	   combinations	   of	   pharmacological	   and	  
psychological	  treatments	  might	  help	  make	  best	  use	  of	  existing	  antidepressant	  drugs	  and	  reduce	  the	  number	  
of	  treatment-­‐resistant	  patients.	  	  	  The	  network	  hypothesis	  of	  antidepressant	  action	  presented	  here	  proposes	  
that	  recovery	  from	  depression	  and	  related	  mood	  disorders	   is	  a	  gradual	  process	  that	  develops	  slowly	  and	   is	  
facilitated	  by	  	  	  structured	  guidance	  and	  rehabilitation.	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Monoamine	   oxidase	   inhibitors	   and	   tricyclic	  
antidepressants,	   the	   first	   effective	   antidepressant	   drugs,	  
were	  discovered	  over	  fifty	  years	  ago,	  but,	  remarkably,	   it	   is	  
still	   unclear	   exactly	   how	   they	   contribute	   to	   recovery	   from	  
depression.	   	   Recognition	   that	   both	   drug	   classes	   increased	  
brain	   levels	   of	   monoamines	   formed	   the	   basis	   for	   the	  
monoamine	  hypothesis	  of	  depression,	  which	  proposed	  that	  
this	  condition	  was	  caused	  by	  a	  deficiency	  in	  monoaminergic	  
neuromodulators	   and	   that	   antidepressant	   drugs	   act	   by	  
replenishing	  them1.	  This	  hypothesis	  has	  dominated	  thinking	  
about	   mood	   disorders	   ever	   since,	   albeit	   becoming	   more	  
focused	   on	   serotonin	   levels	   since	   the	   clinical	   success	   of	  
selective	   serotonin	   reuptake	   inhibitors.	   Even	   theories	   not	  
focused	   on	   monoamines	   have	   conceptualized	   depression	  
(and	   other	   psychiatric	   conditions)	   as	   being	   caused	   by	   too	  
little	  or	  too	  much	  of	  a	  single	  molecule	  that	  is	  normalized	  by	  
successful	  treatment.	  	  
It	   has	   long	   been	   recognized,	   however,	   that	  
despite	   rapid	   drug-­‐induced	   elevations	   of	   monoamine	  
levels,	   symptom	   improvement	   requires	   weeks	   of	  
antidepressant	  treatment.	  	  Although	  a	  tremendous	  amount	  
of	   information	   is	   available	   about	   the	   pharmacology	   of	  
antidepressant	   drugs	   and	   their	   early	   direct	   biochemical	  
effects2-­‐4,	   less	   is	   known	   about	   the	   neurobiological	   and	  
structural	   changes	   that	   temporally	   correlate	   with	   their	  
clinical	   time	   course.	   Critically,	   a	   better	   comprehension	   of	  
the	   delayed	   neural	   changes	   that	   mediate	   the	   beneficial	  
effects	   of	   antidepressants	   will	   instruct	   us	   in	   how	   best	   to	  
maximize	  the	  usefulness	  of	  these	  drugs	  in	  the	  clinic.	  
During	   the	   last	   decade,	   neuroscientists	   have	  
worked	  hard	  to	  redress	  this	  balance	  and,	  as	  a	  result,	  focus	  
has	  shifted	  to	  neuronal	  plasticity,	  neurogenesis	  in	  the	  adult	  
brain,	  and	  to	  the	  ability	  of	  antidepressants	  to	  regulate	  the	  
expression	  of	   genes	   related	   to	   plasticity	   and	   resilience5-­‐10.	  
However,	   it	   remains	  unclear	  how	  exactly	   increased	  neural	  
plasticity	  influences	  mood.	  
This	   review	   will	   present	   the	   growing	   evidence	  
that	   antidepressants	   impact	   plasticity	   and	   will	   focus	   on	  
recent	   findings	   suggesting	   that	   antidepressants	   reactivate	  
juvenile-­‐like	  plastic	  state	  in	  the	  adult	  brain.	  	  The	  possibility	  
that	  this	  network	  level	  reactivation	  of	  plasticity	  might	  be	  an	  
essential	  part	  of	   the	   therapeutic	  action	  of	  antidepressants	  
will	   be	   proposed	   and	   the	   implications	   of	   this	   will	   be	  
discussed.	  	  
	  
Antidepressants	  reactivate	  a	  juvenile-­‐like	  
plasticity	  in	  adult	  brain	  
All	   brain	   functions,	   including	   cognition	   and	   emotions,	   are	  
based	   on	   information	   processing	   and	   storage	   in	   neural	  
networks.	   	   Although	   neurotransmitters	   mediate	  
information	  transfer	  between	  neurons,	   it	   is	  the	  wiring	  and	  
activity	   of	   these	   networks,	   not	   the	   levels	   of	  
neurotransmitters,	   that	   underlies	   information	   processing.	  
Neuronal	   plasticity	   mediates	   structural	   and	   functional	  
changes	  in	  these	  networks,	  and	  experience-­‐dependent	  	  
Box: Visual cortex as a model of neuronal 
network plasticity. 
Network plasticity refers to the ability of the nervous 
system to change the structure and function of 
neuronal networks in response to environmental 
experiences.  While the basic anatomical plan of 
neuronal projections is largely directed by genetic 
influences, the fine-tuning of the network takes place 
under environmental guidance11, 12, 92. Neuronal 
networks form and are constantly shaped through an 
activity-dependent process whereby individual 
experiences and neuronal activity selects and 
strengthens those synapses which optimally mediate 
the presented environmental information while the 
connections that mediate random noise are weakened 
and pruned away11, 93.  Network plasticity is active 
during critical periods of postnatal life and become 
much more restricted after their closure in adulthood14-
16.  
Mammalian visual cortex has over the last few 
decades become one of the best-characterized 
models of neuronal network plasticity.  During 
postnatal development in primates and cats, visual 
inputs from each eye segregate into alternating eye-
specific regions in the primary visual cortex, called 
ocular dominance (OD) columns, such that each 
column receives predominant innervation from one 
eye only14-16.  This segregation process takes place 
during a critical period of early postnatal development 
and requires the balanced use of both eyes14.  If vision 
of one eye is blocked by eye patching during the 
critical period, the more active inputs from the open 
eye take over the majority of the visual cortex and the 
closed eye loses its connectivity, thereby becoming 
poor in vision, or amblyopic.  If the patch is removed 
during the critical period and the use of the weaker eye 
is encouraged by patching the better eye, the vision of 
the amblyopic eye can be recovered. However, if the 
patching extends beyond the end of the critical period, 
amblyopia becomes permanent and cannot be revised 
by patching of the better eye. Thus, in this process a 
perfectly healthy eye, which has grown its projections 
to the visual cortex completely normally, loses its 
connectivity and becomes permanently deficient only 
because it is deprived of activation during the critical 
period. In humans, patching of the better eye is being 
successfully used for the prevention of amblyopia 
diagnosed in young children, but it is ineffective in 
adults.  Although rodent visual cortex does not show 
OD columns, response to visual stimulation and visual 
acuity are impaired by monocular deprivation during 
early life. This model system has been extensively 
utilized to reveal the underlying mechanisms of the 
plastic process whereby the visual experience, through 
the activity of retinal projections, gradually shapes 
neuronal networks within the visual cortex to optimally 
represent the visual environment.  It is widely 
considered that similar processes govern the 
development and tuning of neuronal connectivity in 




plasticity	  tunes	  the	  networks	  to	  represent	  environmental	  
input	  during	  development	  and	  underlies	  our	  ability	  to	  learn	  
in	  adulthood11,	  12	  (Box	  1).	  	  It	  is	  increasingly	  recognized	  that	  
mood	   disorders	   are	   often	   associated	   with	   structural	  
abnormalities	   within	   the	   networks	   implicated	   in	  
depression13,	   raising	   the	   possibility	   that	   changes	   in	  
information	   processing	   are	   a	   key	   component	   of	   these	  
conditions.	  
The	   seminal	   work	   of	   Hubel	   and	   Wiesel	   in	   the	  
early	   1960s	   established	   that	   sensory	   experience	   shapes	  
how	   the	   brain	   develops,	   demonstrating	   that	   visual	   input	  
molds	  the	  structure	  and	  functionality	  of	  the	  networks	  that	  
process	   that	   information14.	   	   Additionally,	   they	   clearly	  
showed	  that	  the	  degree	  to	  which	  the	  brain	  can	  be	  changed	  
by	   experience	   was	   variable	   and	   age-­‐dependent,	   with	  
plasticity	  highest	  during	   “critical	   periods”	   that	  occurred	  at	  
stereotyped	   developmental	   stages14-­‐16.	   	   Subsequently,	  
similar	   critical	   periods	   have	   been	   observed	   in	   numerous	  
neural	   systems,	   including	   emotional	   processing	   centers16,	  
17,	  suggesting	  that	  visual	  cortical	  plasticity	  might	  be	  used	  as	  
a	   model	   to	   investigate	   the	   mechanisms	   that	   mediate	  
plasticity	  in	  brain	  regions	  that	  are	  more	  difficult	  to	  examine	  
in	   the	   living	   animals	   or,	   even	   more	   so,	   in	   humans.	   	   Use-­‐
dependent	   plasticity	   continues	   to	   take	   place	   in	   adulthood	  
and	   this	   adult	   plasticity	   underlies	   our	   ability	   to	   form	  
memories	  and	  learn.	  	  However,	  after	  the	  closure	  of	  critical	  
periods,	   plasticity	   is	  more	   restricted	   than	  during	   the	   early	  
life	  and	  is	  mostly	  confined	  to	  changes	  in	  strength	  of	  existing	  
synapses,	   either	   strengthening	   (long-­‐term	   potentiation,	  
LTP)	  or	  weakening	   (long-­‐term	  depression,	   LTD)18.	   LTP,	   LTD	  
and	   learning	   are	   differentially	   modified	   by	   internal	   or	  
external	   experiences	   such	   as	   stress,	   depression	   and	  
antidepressant	  drugs	  19-­‐21.	  
New	  evidence	  published	  during	  the	  last	  few	  years	  
suggests	   that	   recovery	   from	   depression,	   rather	   than	  
resulting	   from	   an	   increase	   or	   a	   decrease	   in	   the	  
concentration	   of	   a	   single	  molecule	   or	   the	   expression	   of	   a	  
particular	   gene,	   reflects	   structural	   and	   functional	   changes	  
in	   critical	   neuronal	   networks	   that	   allow	   them	   to	   better	  
adapt	   to	   environmental	   conditions22-­‐24.	   	   According	   to	   this	  
network	   hypothesis,	   mood	   disorders	   might,	   at	   least	  
partially,	   reflect	  an	   inability	  of	   the	  neuronal	  networks	  that	  
guide	   mood-­‐related	   behavior	   to	   optimally,	   or	  
appropriately,	  adjust	  to	  inputs	  from	  the	  external	  world.	  	  In	  
this	   framework,	   the	   early	   chemical	   effects	   of	  
antidepressants	   initiate	   a	   process	   whereby	   neuronal	  
networks,	   guided	   by	   activity,	   readjust	   their	   structure	   to	  
better	   represent	   the	   external	   and	   internal	   milieu22.	  	  	  
Consistent	   with	   the	   delayed	   emergence	   of	   the	   clinical	  
effects	   of	   antidepressant	   drugs;	   this	   process	   would	   take	  
weeks	   either	   to	   occur	   or	   to	   be	   of	   sufficient	  magnitude	   to	  
alter	  mood	  and	  behavior.	  
To	  directly	  address	  the	  effects	  of	  antidepressant	  treatment	  
of	  plasticity,	  Lamberto	  Maffei	  and	  his	  collaborators	  used	  rat	  
primary	   visual	   cortex	   was	   as	   an	   experimental	   system,	  
because	   of	   the	   wealth	   of	   data	   relating	   to	   experience-­‐
dependent	  plasticity	   in	  this	  system	  (see	  Box	  1).	   	  Rats	  were	  
chronically	  treated	  with	  fluoxetine	  and	  its	  effects	  on	  these	  
networks	   were	   assessed	   using	   well-­‐established	   assays25.	  	  
When	  adult	   rats	  were	   treated	  with	   fluoxetine,	   closing	  one	  
eye	   produced	   a	   dramatic	   shift	   in	   the	   responsiveness	   of	  
visual	  cortical	  neurons	  in	  favor	  of	  the	  open	  eye,	  a	  response	  
normally	   only	   seen	   during	   the	   early	   postnatal	   critical	  
   3 
period25	   (Box	   1).	   	   Furthermore,	   fluoxetine-­‐induced	  
reactivation	   of	   such	   critical	   period-­‐like	   plasticity	   also	  
allowed	   functional	   recovery	   of	   a	   network	   that	   was	  
miswired	   during	   postnatal	   development:	   	   When	   one	   eye	  
was	  kept	  closed	  during	  early	   life	  but	  opened	  in	  adulthood,	  
it	   only	   generated	  weak	   visual	   response	   (amblyopic)	   in	   the	  
visual	   cortex	  even	  when	   its	   use	  was	  enforced	  by	  patching	  
the	  previously	  open	  healthy	  eye.	  	  However,	  when	  patching	  
of	  the	  better	  eye	  was	  combined	  with	  fluoxetine	  treatment	  
in	   adult	   rats,	   visual	   acuity	   of	   the	   reopened	   eye	   was	   fully	  
recovered25.	   	   Again,	   recovery	   of	   visual	   acuity	   of	   an	  
amblyopic	   eye,	   both	   in	   rats	   and	   humans,	   is	   normally	   only	  
possible	   if	   the	   eye	   is	   opened	   and	   the	   other	   eye	   patched	  
during	  the	  juvenile	  critical	  period.	  	  	  
These	   remarkable	   findings	   demonstrate	   that	  
fluoxetine	   treatment	   in	   adult	   animals	   reactivates	   a	   critical	  
period-­‐like	  plasticity,	  which	  can	  facilitate	  the	  reorganization	  
and	   functional	   recovery	   of	   a	   network	   that	   was	   miswired	  
during	  development.	   	   Importantly,	   recovery	  only	  occurred	  
when	   the	  drug	   treatment	  was	   combined	  with	   appropriate	  
rehabilitation,	  such	  as	  the	  patching	  of	  the	  better	  eye.	  	  	  	  	  
Interestingly,	   living	   in	   a	   stimulating	   environment	  may	   also	  
boost	  neuronal	  plasticity	  in	  ways	  that	  parallel	  the	  effects	  of	  
fluoxetine	   treatment.	   	   In	   a	   study	   where	   adult	   rats	   were	  
transferred	   from	   their	   home	   cage	   to	   an	   enriched	  
environment,	   there	   was	   also	   an	   induction	   of	   plasticity	   in	  
the	  adult	  visual	  cortex	  and	  a	  recovery	  in	  the	  visual	  acuity	  of	  
an	  amblyopic	  eye26.	  	  In	  this	  context	  it	  is	  interesting	  to	  note	  
that	   treatment	   of	   depressed	   patients	   with	   placebo	   brings	  
about	   a	   noticeable	   response	   that	   in	   mild	   depression	   is	  
often	   comparable	   to	   that	   produced	   antidepressants27,	   28.	  	  
The	   magnitude	   of	   placebo	   response	   correlates	   positively	  
with	   the	   number	   of	   visits	   to	   a	   study	   assistant	   during	   a	   6-­‐
week	   trial	   and	   effect	   of	   these	   follow-­‐up	   visits	   represent	  
about	   40%	   of	   the	   total	   placebo	   effect29,	   suggesting	   that	  
social	  interaction	  has	  a	  large	  impact	  on	  the	  placebo	  effect.	  	  
It	  is	  possible	  that	  such	  interaction	  might	  be	  experienced	  as	  
enrichment	   by	   some	   patients,	   which	   might,	   at	   least	  
partially,	   underlie	   the	   response	   to	   placebo	   in	  
antidepressant	   trials.	   	   Furthermore,	   placebo	   response	   is	  
not	  immediate,	  as	  would	  be	  expected,	  but	  shows	  a	  delayed	  
time	   course	   similar	   to	   that	   of	   antidepressant	   drugs30,	   31,	  
suggesting	   a	   possibility	   that	   similar	   mechanisms	   might	  
underlie	   the	   response	   to	   the	   active	   drug	   and	   the	  
experienced	  enrichment	  produced	  by	  the	  inactive	  placebo,	  
even	  though	  maximal	  responses	  would	  be	  different.	  	  
To	   investigate	   if	   antidepressant	   treatment	  
reactivates	   juvenile-­‐like	   plasticity	   not	   only	   in	   the	   visual	  
cortex	  but	  also	  in	  mood-­‐relevant	  networks,	  a	  recent	  series	  
of	   experiments	   used	   fear	   conditioning	   and	   an	   extinction-­‐
training	   paradigm32.	   	   Pairing	   a	   neutral	   tone	   with	   a	   mild	  
foot-­‐shock	   quickly	   conditions	   mice	   to	   be	   fearful	   of	   that	  
tone,	   which	   is	   manifest	   in	   the	   extent	   to	   which	   they	   stop	  
moving	  and	  freeze	  when	  the	  tone	  is	  played33.	  	  Analogous	  to	  
exposure	   therapy	   for	   phobias	   in	   humans,	   repeated	  
exposure	   to	   the	   tone	   alone,	   without	   a	   paired	   foot-­‐shock,	  
gradually	   extinguishes	   the	   freezing	   response	   in	   rodents.	  
However,	   the	   learned	   extinction	   is	   not	   permanent	   and,	  
again	   comparable	   to	   human	   exposure	   therapy	   where	  
spontaneous	   recovery	   of	   phobia	   after	   extinction	   is	  
problematic34,	   playing	   a	   tone	   after	   a	   period	   of	   one	   week	  
again	   produces	   a	   freezing	   response	   indicating	   a	  
spontaneous	  recovery	  of	  fearfulness35.	  	  	  
Extinction	  training	  after	  fear	  conditioning	  in	  mice	  produced	  
only	   short-­‐lasting	  effects,	   but	   in	   combination	  with	   chronic	  
fluoxetine	   treatment,	   extinction	   training	   brought	   about	   a	  
long-­‐lasting	   decrease	   of	   the	   fear	   response32.	   	   Fluoxetine	  
treatment	   alone	   did	   not	   affect	   post-­‐conditioning	   freezing	  
responses.	  	  	  A	  recent	  study	  showed	  that	  extinction	  training	  
produces	   long-­‐lasting	   effects	   when	   fear	   conditioning	   is	  
induced	  and	  extinguished	  in	  early	  postnatal	  life36,	  indicating	  
that	  there	  is	  a	  developmentally	  regulated	  critical	  period	  for	  
efficient	   extinction.	   	   These	   data	   suggest	   that	   chronic	  
fluoxetine	  treatment	  reactivates	  a	  juvenile-­‐like	  plasticity	  in	  
mood-­‐related	   neuronal	   networks,	   which	   in	   combination	  
with	   extinction	   training	   leads	   to	   long-­‐lasting	   beneficial	  
effects.	   Indeed,	   evidence	   was	   provided	   that	   fluoxetine	  
induces	   a	   plastic	   state	   in	   the	   basolateral	   amygdala,	  
reminiscent	   of	   that	   present	   during	   early	   life32.	   	   These	  
findings	   are	   consistent	   with	   observations	   that	   combined	  
antidepressant	   treatment	   and	   exposure	   therapy	   worked	  
better	   in	   the	   treatment	   of	   patients	   with	   posttraumatic	  
stress	   disorder	   than	   either	   treatment	   alone37,	   although	   a	  
significant	  beneficial	  effect	  of	  a	  combination	  has	  not	  been	  
seen	  in	  all	  studies38,	  39.	  	  
The	   key	   point	   of	   the	   network	   hypothesis	   is	   that	  
the	   neurobiological	   alteration	   that	   underlies	   improved	  
affect	   is	   the	  operational	   state	  of	   the	  neural	  networks	   that	  
underlie	   mood	   and	   related	   information	   processing.	  	  
Although	  it	  argues	  against	  equating	  mood	  with	  the	  level	  of	  
any	   particular	   signaling	   molecule	   or	   protein,	   it	   will	   be	  
instructive	   to	   determine	   the	   mechanisms	   by	   which	  
antidepressants	   enhance	   network	   plasticity.	   	   In	   both	   the	  
visual	  cortex	  and	  the	  amygdala	  of	  adult	  animals,	  long-­‐term	  
potentiation	   of	   synaptic	   transmission	   by	   high	   frequency	  
stimuli	   is	  difficult	   to	   induce	  but	  was	  clearly	  observed	  after	  
fluoxetine	   treatment25,	   32.	   	   Brain-­‐derived	   neurotrophic	  
factor	   (BDNF)	   was	   elevated	   and	   at	   least	   partially	  
contributed	   to	   the	   changes	   observed	   in	   both	   systems.	  	  
Serotonin,	   acting	   through	  5HT1A	   receptors,	  was	   shown	   to	  
play	  a	  critical	  role	  in	  the	  plastic	  effects	  of	  fluoxetine	  in	  the	  
visual	   cortex40.	   Levels	   of	   the	   inhibitory	   neurotransmitter	  
GABA	  were	  reduced	  by	  fluoxetine	  in	  visual	  cortex,	  and	  the	  
drug’s	   effects	   were	   attenuated	   by	   augmenting	   GABAergic	  
function25.	  	  An	  independent	  group	  showed	  that	  fluoxetine-­‐
induced	   plasticity	   in	   visual	   cortex	   was	   associated	   with	  
increases	   in	   both	   the	   elongation	   and	   retraction	   of	  
interneuron	   dendritic	   branches41,	   suggesting	   that	   synaptic	  
turnover	  on	  GABAergic	  neurons	  is	  elevated.	  It	  is,	  therefore,	  
evident	   that	   the	   interplay	   between	   multiple	  
neurotransmitter	   and	   modulator	   systems	   is	   mediating	  
effects	   on	   plasticity.	   	   Determining	   the	   routes	   and	  
interactions	   by	   which	   enhanced	   plasticity	   is	   achieved	  
should	   provide	   clues	   for	   developing	   novel	   therapeutic	  
agents	  that	  can	  better	  achieve	  clinical	  goals.	  
In	   addition	   to	   fluoxetine,	   histone	   deacetylase	  
(HDAC)	   inhibitors	   have	   also	   been	   shown	   to	   reactivate	   a	  
critical	  period-­‐like	  plasticity	  in	  the	  rodent	  visual	  cortex40,	  42,	  
43.	  	  HDAC	  inhibition	  increases	  acetylation	  of	  histone	  tails,	  an	  
epigenetic	   response	   that	   promotes	   gene	   transcription.	  	  	  
Notably,	   Nestler’s	   lab	   has	   shown	   that	   chromatin	  
remodeling	   and	   histone	   acetylation	   control	   behavioral	  
adaptations	  to	  chronic	  emotional	  stimuli44-­‐46	  and	  that	  HDAC	  
inhibitors	   show	   antidepressant-­‐like	   activity	   in	   animal	  
models	   of	   depression47.	   	   Additional	   studies	   are	  needed	   to	  
assess	  whether	  other	  effective	  antidepressant	   treatments,	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including	   the	   fast-­‐acting	   ketamine24,	  may	   share	   the	   ability	  
to	   reactivate	   juvenile-­‐like	   plasticity	   in	   the	   adult	   brain.	  	  
Finally,	   critical	   period-­‐like	   plasticity	   has	   been	   induced	   in	  
adult	   visual	   cortex	   through	   several	   other	   pharmacological	  
or	   non-­‐pharmacological	   methods,	   including	   exposure	   to	  
enriched	   environment26,	   dark	   exposure48,	   caloric	  
restriction49,	   treatment	   with	   cholinesterase	   inhibitors50,	  
and	   local	   injection	  of	   nerve	   growth	   factor51,	   52,	   insulin-­‐like	  
growth	  factor53	  or	  enzymes	  degrading	  perineural	  nets54	  (for	  
review,	   see55).	   	   It	   remains	   unclear	   whether	   any	   of	   these	  
treatments	  might	  have	  an	  influence	  on	  mood	  in	  humans.	  	  
	  
Do	   antidepressants	   induce	   juvenile-­‐like	  
plastic	  state	  in	  human	  brain?	  	  	  
If	   antidepressants,	   drugs	   used	   by	   millions	   of	   people	   over	  
several	  decades,	  reactivate	  juvenile-­‐like	  plasticity	  in	  human	  
brains,	  how	  is	  it	  possible	  that	  such	  effects	  could	  have	  gone	  
unnoticed?	   	  One	  possibility	   is	   that	  the	   induced	  plasticity	   is	  
detectable	   only	   after	   combined	   rehabilitation	   or	   training.	  	  
Another	  is	  that	  these	  changes	  are	  subtle	  and	  have	  not	  been	  
extensively	   investigated.	   	   However,	   there	   are	   reports	  
indicating	  that	  antidepressants,	  indeed,	  induce	  plasticity	  in	  
adult	  human	  cortex.	  	  For	  example,	  Normann	  and	  coworkers	  
used	   EEG	   to	   record	   visually	   evoked	   potentials	   from	   the	  
visual	   cortex	   of	   depressed	   patients,	   control	   subjects,	   and	  
healthy	   volunteers	   given	   the	   antidepressant	   sertraline56.	  	  
They	  found	  they	  could	  alter	  the	  visual	  cortical	  response	  to	  a	  
visual	   stimulus	   by	   presenting	   it	   repeatedly	   at	   high	  
frequency.	  Using	  the	  magnitude	  of	  this	  change	  as	  an	  index	  
of	   neuronal	   plasticity,	   they	   found	   that	   depressed	   patients	  
had	   lower	   levels	  of	  plasticity	   than	  controls.	   	  Strikingly,	   the	  
healthy	   volunteers	   given	   sertraline	   had	   significantly	  
elevated	   signs	   of	   plasticity	   in	   their	   visual	   cortices56,	   in	   a	  
manner	   similar	   to	   that	   observed	   in	   the	   visual	   cortex	   of	  
adult	  rats	  treated	  with	  fluoxetine25.	  	  	  
These	   findings	   suggest	   that	   chronic	   treatment	  
with	   antidepressants	   enhances	   neuronal	   plasticity	   in	   the	  
visual	   cortex	   of	   both	   humans	   and	   rodents.	   	   Whether	   the	  
effects	   seen	   in	   humans	   reflect	   a	   reactivation	   of	   early	   life-­‐
like	  plasticity	  remains	  to	  be	  tested.	  	  	  An	  ongoing	  clinical	  trial	  
on	  whether	  antidepressants	   can	  be	  used	   in	   the	   treatment	  
of	  human	  amblyopia	  in	  adulthood57	  may	  eventually	  provide	  
a	  direct	  answer	  to	  this	  question.	  	  
	  
Is	   there	   evidence	   for	   a	   network	  
abnormality	  in	  depression?	  
If	   recovery	   from	  depression	   reflects	  network	   rewiring,	   are	  
mood	   disorders,	   at	   least	   partially,	   produced	   by	   neuronal	  
networks	   maladjusted	   to	   the	   realities	   of	   the	   external	  
world?	   	   Such	   changes	   in	   network	   structure	   and	   function	  
might	   be	   the	   result	   of	   adverse	   early	   life	   experiences,	  
continuous	  stress	  in	  adulthood	  or	  genetic	  factors58.	  	  	  
A	   number	   of	   studies	   have	   shown	   that	   there	   are	  
morphological	   abnormalities	   in	   the	   brains	   of	   depressed	  
patients	   within	   the	   circuitry	   connecting	   the	   medial	  
prefrontal	   cortex,	   amygdala	   and	   hippocampus,	   a	   circuitry	  
that	  has	  been	  implicated	  in	  depression13,	  59.	  Changes	  in	  gray	  
matter	  volume,	  neuronal	  organization,	  electrophysiological	  
activity	  and	  receptor	  pharmacology	  have	  been	  observed	  in	  
these	   regions	   in	   depressed	   patients13,	   59,	   60.	   	   Furthermore,	  
diffusion	   tensor	   imaging	   has	   revealed	   white	   matter	  
abnormalities	   in	   these	   circuits	   in	   depressed	   patients61-­‐63,	  
which	  suggests	  abnormalities	  in	  the	  connectivity	  within	  the	  
mood-­‐relevant	   networks.	   	   Activity	   of	   different	   regions	   in	  
these	   circuits	   is	   selectively	   influenced	   in	   depressed	  
patients:	  activity	  is	  reduced	  in	  the	  dorsal	  system,	  including	  
the	   hippocampus	   and	   the	   dorsolateral	   prefrontal	   cortex,	  
but	   increased	   in	   the	   ventral	   system,	   including	   the	  
amygdala,	  the	  ventral	  striatum	  and	  the	  subgenual	  cingulate	  
cortex	   20,	   64.	   	   Consistent	   with	   this,	   BDNF	   produces	  
antidepressant-­‐like	   effects	   when	   injected	   into	  
hippocampus65,	   but	   shows	   prodepressant	   effects	   when	  
expressed	   in	   the	   dopaminergic	   projection	   neurons	  
projecting	   to	   the	   nucleus	   accumbens	   in	   the	   ventral	  
striatum66,	  67.	  	  
It	   should	   be	   noted	   that	   a	   structurally	   normal	  
network	   might	   still	   represent	   abnormal	   function.	   	   Cortex	  
that	   receives	   abnormal	   environmental	   input	   during	   its	  
critical	   period	   proceeds	   through	   an	   otherwise	   normal	  
developmental	  process	  to	  faithfully	  represent	  the	  abnormal	  
information.	  	  When	  active	  inputs	  are	  strengthened	  and	  less	  
active	   ones	   simultaneously	   weakened,	   structural	   changes	  
may	  cancel	  each	  other	  out	  and	  no	  net	  volume	  changes	  may	  
be	   observed68,	   even	   though	   network	   structure	   is	   altered.	  
Therefore,	   it	   becomes	   very	   difficult	   to	   anatomically	   or	  
biochemically	   differentiate	   a	   functionally	   abnormal	  
network	   from	   one	   that	   was	   guided	   by	   a	   normal	  
environment69,	   70.	   	  While	   in	  experimental	  systems	   input	   to	  
the	   visual	   cortex	   can	   be	   straightforwardly	  manipulated	   to	  
assess	  changes	  to	  the	  network	  structure,	  there	  is	  no	  simple	  
way	  of	  similarly	  altering	  inputs	  to	  higher	  brain	  areas	  such	  as	  
the	   prefrontal	   cortex.	   	   It	   should	   be	   noted	   that	   the	   visual	  
cortices	   of	   amblyopic	   patients	   with	   one	   eye	   essentially	  
blind	   show	   only	   modest	   and	   non-­‐specific	   differences	   in	  
cortical	   thickness	   compared	   with	   binocular	   subjects70,	   71.	  	  
This	   small	   reduction	   in	   grey	   matter	   volume	   in	   the	  
amblyopic	  visual	  cortex	  resembles	  changes	  observed	  in	  the	  
medial	   prefrontal	   cortex	   of	   depressed	   patients13.	   	   	   One	  
possible	   solution	   to	   this	   problem	   is	   to	   use	   correlates	   of	  
plasticity	  as	  indicators:	  LTP	  and	  LTD	  have	  successfully	  been	  
used	  a	  correlates	  of	  plasticity	  in	  animal	  experiments19	  and	  a	  
recent	   innovative	   study	   used	   learning	   as	   a	   correlate	   of	  
plasticity	   in	  depressed	  patients20	  pointing	   towards	   indirect	  
measures	  to	  overcome	  this	  problem.	  
	  
Implications	   of	   the	   network	   hypothesis	   of	  
antidepressant	  action	  	  
The	  network	  hypothesis	   of	   antidepressant	   action	   suggests	  
that	   antidepressant	   treatment,	   by	   enhancing	   plasticity	  
within	   key	   networks,	   would	   create	   circumstances	   where	  
these	  malfunctioning	   networks	   can	   be	   fixed,	   and	   that	   the	  
chance	   of	   clinical	   improvement	   is	   maximized	   if	   a	   positive	  
environmental	   model	   is	   present	   to	   guide	   the	   network	  
towards	   optimal	   function22.	   	   This	   hypothesis	   has	   several	  
important	  practical	  implications.	  
First,	   a	   combination	   of	   antidepressants	   with	  
psychotherapy	  has	  been	  shown	  to	  work	  better	  than	  either	  
of	  the	  treatments	  alone	  in	  most	  studies37,	  72-­‐74,	  although	  not	  
in	  all38,	  75	  and	  long-­‐term	  effects	  of	  combined	  treatment	  has	  
been	   reported	   to	   be	   inferior	   to	   that	   of	   psychotherapy	  
alone39.	   	  Furthermore,	  some	  patients	  remain	  resistant	  also	  
to	   a	   combined	   treatment.	   	   Nevertheless,	   the	   network	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hypothesis	  might	  provide	  a	  neurobiological	  basis	  for	  such	  a	  
combined	   effect.	   	   In	   the	   experimental	   studies	   the	   visual	  
acuity	  or	  fear	  response,	  fluoxetine	  treatment	  alone	  had	  no	  
effects,	   drug	   treatment	   had	   to	   be	   combined	   with	  
environmental	   rehabilitation	   to	   bring	   about	   beneficial	  
effects25,	   32.	   	   Similarly,	   rehabilitation	   alone	   produced	   only	  
transient	   effects,	   long-­‐term	   effects	   were	   observed	   only	  
when	   rehabilitation	   was	   combined	   with	   fluoxetine	  
treatment	   32.	   	   Thus,	   drug	   therapy	   and	   rehabilitation	  were	  
closely	   entwined	   and	   supported	   the	   action	   of	   each	   other.	  
These	  data	  suggest	  that	  drug	  treatment	  alone	  is	  insufficient	  
for	   mood	   recovery,	   and,	   hence,	   that	   pharmacotherapy	  
needs	  to	  be	  combined	  with	  proper	  environmental	  guidance	  
in	   order	   to	   achieve	  maximal	   benefit.	   	   Psychotherapy	   such	  
as	   cognitive	   behavioral	   therapy	   (CBT)	   may	   provide	   such	  
guidance,	  but	  other	  types	  of	  rehabilitation,	  including	  group	  
therapy	  may	  also	  be	  beneficial.	  	  	  
It	   is	   conceivable	   that	   some	   depressed	   patients	  
live	   in	   environments	   with	   features	   that	   beneficially	   guide	  
the	  plastic	  network	   in	   the	  absence	  of	   therapy	  provided	  by	  
health	   care	   professionals.	   At	   least	   a	   third	   of	   depressed	  
patients	   do	   not	   respond	   to	   antidepressants	   and	   this	   has	  
inspired	   the	   search	   for	   novel	   antidepressants	   with	   new	  
mechanisms	  of	  action2-­‐4,	  76.	  	  However,	  it	  is	  also	  possible	  that	  
current	   treatment	   strategies	   are	   not	   taking	   the	   best	  
advantage	   of	   the	   existing	   drugs.	   	   If	   the	   effectiveness	   of	  
antidepressant	   treatment	   is	   enhanced	   by	   environmental	  
guidance,	   it	   is	   possible	   that	   treatment-­‐resistant	   patients	  
may	   respond	   to	   the	   drug,	   but	   do	   not	   experience	   any	  
guidance	   that	   would	   support	   recovery.	   	   Perhaps	   patients	  
who	  have	  supportive	  family	  or	  other	  social	  contacts	  benefit	  
from	  these	  interactions	  and	  therefore	  respond	  positively	  to	  
drug	  treatment	  whereas	  patients	  lacking	  a	  positive	  support	  
network	   are	   at	   increased	   risk	   of	   becoming	   treatment-­‐
resistant.	   	   In	   support	   of	   this	   notion,	   a	   study	   of	   the	  
predictors	   of	   remission	   with	   antidepressant	   treatment	  
found	  that	  patients	  with	  a	  family	  and	  a	  job	  benefited	  most	  
from	   antidepressant	   treatment76.	   	   Even	   though	  
antidepressants	   have	   been	   given	   to	   depressed	   patients	   in	  
hundreds	   of	   clinical	   trials,	   we	   know	   little	   about	   what	   the	  
patients	  did	  while	  taking	  the	  drug	  and	  whether	  their	   living	  
conditions	   might	   correlate	   with	   the	   treatment	   outcome.	  	  
Further	   studies	   are	   needed	  where	   the	   living	   environment	  
and	   social	   contacts	   of	   patients	   receiving	   antidepressants	  
are	  evaluated	  and	  correlated	  with	  the	  treatment	  response.	  	  
The	   network	   hypothesis	   provides	   strong	   support	   for	  
attempts	  to	  organize	  health	  care	  services	  in	  such	  a	  manner	  
that	   patients	   diagnosed	   with	   mood	   disorders	   would	   not	  
only	   receive	   drug	   treatment,	   but	   would	   also	   from	   the	  
beginning	   receive	   psychotherapy	   or	   another	   form	   of	  
psychological	   assistance	   to	   optimally	   support	   the	  
facilitating	  effects	  of	  antidepressant	  drugs	  on	  plasticity	  and	  
mood	  recovery77,	  78	  
It	  should	  also	  be	  noted	  that	  reactivation	  of	  critical	  
periods	   should	   only	   work	   once	   they	   are	   closed.	   	   There	   is	  
currently	   little	   information	   on	   whether	   antidepressants	  
might	   influence	   plasticity	   in	   children	  while	   critical	   periods	  
are	   still	   open.	   	   A	   recent	   study	   provided	   evidence	   that	  
prenatal	  antidepressant	  treatment	  accelerated	  the	  opening	  
of	  a	  critical	  period	  for	  language	  learning79,	  which	  resembles	  
the	  findings	  that	  physical	  enrichment	  in	  a	  form	  of	  massage	  
accelerates	   the	   maturation	   of	   visual	   system	   in	   preterm	  
human	   babies	   as	   well	   as	   in	   rats80.	   	   Early	   exposure	   to	  
antidepressants	  have	  been	   found	  to	  produced	   long-­‐lasting	  
behavioral	   effects	   in	   rodents81-­‐84,	   but	   whether	   these	  
findings	   are	   related	   to	   any	   effects	   on	   the	   regulation	   of	  
critical	  periods	  remains	  to	  be	  investigated.	  	  	  
Finally,	  it	  will	  be	  important	  to	  investigate	  whether	  
a	   window	   of	   plasticity	   remains	   open	   as	   long	   as	   drug	  
treatment	   lasts	  or	  whether	   it	   spontaneously	  closes	  after	  a	  
while	   even	   upon	   continuous	   treatment.	   	   Mood	   disorders	  
typically	   show	   a	   chronic	   and	   relapsing	   course,	   where	  
affective	   episodes	   tend	   to	   become	   increasingly	  
independent	   of	   environmental	   stressors.	   	   Whether	   this	  
relapsing	  course	   is	   somehow	  related	  to	   loss	  of	  drug	  effect	  
on	  plasticity	  is	  an	  important	  topic	  for	  research	  in	  the	  future.	  	  	  
The	  second	  prediction	  of	  the	  network	  hypothesis	  
is	   that	   antidepressants	   would	   be	   useful	   in	   any	   condition	  
where	   neuronal	   network	   plasticity	  would	   expedite	   clinical	  
recovery.	   	   Indeed,	   the	   clinical	   efficacy	   of	   antidepressant	  
drugs	   is	  not	   limited	  to	  mood	  disorders;	   they	  are	  also	  used	  
in	  a	  wide	  variety	  of	  neuropsychiatric	  disorders	  ranging	  from	  
obsessive-­‐compulsive	   and	   post-­‐traumatic	   stress	   disorders	  
to	  chronic	  pain	  and	  eating	  disorders2,	  3.	  	  Furthermore,	  there	  
is	   evidence	   that	   patients	   recovering	   from	   stroke	   benefit	  
from	   antidepressant	   treatment	   while	   undergoing	  
rehabilitation85-­‐87.	   	   These	  data	   suggest	   that	   a	   combination	  
of	   antidepressant	   treatment	   and	   rehabilitation	   might	   be	  
beneficial	   in	   a	   wider	   spectrum	   of	   clinical	   conditions	   than	  
recognized	  today.	  	  
Third,	  antidepressant	   treatment	  appears	   to	  have	  
only	  relatively	  mild	  effects	  on	  mood	  in	  healthy	  subjects88-­‐90,	  
although	   there	   is	   little	   information	   concerning	   long-­‐term	  
effects	   of	   antidepressants	   in	   healthy	   subjects.	   	   This	  
observation	   is	   consistent	   with	   and	   explained	   by	   the	  
network	   hypothesis.	   	   If	   the	   network	   is	   already	   optimally	  
tuned	   to	   the	   environment,	   then	   plasticity	   provided	   by	  
antidepressants	   is	   not	   expected	   to	   change	   that	  
representation,	   if	   anything,	   it	   may	   strengthen	   it.	   	   On	   the	  
other	   hand,	   the	   hypothesis	   predicts	   that	   taking	  
antidepressants	   under	   adverse	   life	   conditions	   might	  
promote	   maladaptive	   plasticity	   and	   train	   the	   network	   to	  
model	   this	   unfavorable	   environment,	  which	  might	   lead	   to	  
deterioration	  rather	  than	  improvement	  in	  the	  clinical	  state.	  	  
Maladaptive	   plasticity	   may	   also	   underlie	   the	   induction	   of	  
mania	   sometimes	   encountered	   in	   bipolar	   patients.	   	   It	   is	  
conceivable	   that	   antidepressant	   treatment	   has	   multiple	  
effects,	   the	  network	  plasticity	  being	   just	  one	  of	   them,	  and	  
the	   net	   effect	   favors	   a	   positive	   treatment	   outcome.	  
Consistent	  with	  this	  notion,	  antidepressant	  treatment	  shifts	  
emotional	   processing	   biases	   towards	   positive	   direction	   in	  
both	  depressed	  patients	  and	  healthy	  volunteers,	  indicating	  
that	   antidepressants	   favor	   a	   shift	   towards	   normative	  
direction90,	  91.	  
Overall,	  these	  new	  findings	  advance	  a	  conceptual	  
shift	  that	  might	  reconcile	  the	  long-­‐standing	  dispute	  of	  “talk	  
vs.	  pill”,	  a	  debate	  that	  continues	  between	  those	  who	  favor	  
psychotherapy	  and	   those	  who	  consider	  drug	   treatment	  as	  
key	   to	   the	   treatment	   of	   mood	   disorders.	   	   If	   talk	   benefits	  
from	  pills	   that	   increase	  plasticity	  and	  pills	   are	  best	   guided	  
by	   talk	   to	   instruct	   the	   plastic	   networks,	   then	   the	   two	  
treatment	   strategies	   perfectly	   complement	   each	   other.	  	  
Rather	  than	  arguing	  whether	  talk	  or	  pill	  is	  better,	  we	  should	  
try	   to	   find	   an	   optimal	   combination	   of	   the	   two	   treatment	  
strategies	  for	  as	  many	  patients	  as	  possible.	  	  
	  
   6 
Conclusions	  
The	   network	   hypothesis	   proposes	   that	   antidepressants	  
achieve	   their	   therapeutic	   effects	   via	   a	   gradual	   process	   in	  
which	   enhanced	   plasticity	   facilitates	   the	   reorganization	   of	  
cortical	   networks	   to	   better	   adjust	   to	   environmental	  
experiences.	  	  The	  hypothesis	  suggests	  that	  antidepressants	  
do	   not	   directly	   improve	   mood,	   but	   by	   reactivating	   a	  
juvenile-­‐like	  state	  of	  plasticity,	  they	  promote	  the	  effects	  of	  
rehabilitation	   and	   psychological	   therapy	   to	   bring	   about	  
mood	  recovery.	  	  Thus,	  the	  antidepressants	  action	  might	  be	  
likened	   to	   that	   of	   anabolic	   steroids:	   steroids	   facilitate	   a	  
process	  where	  exercise	   increases	  muscle	  growth,	  but	   they	  
are	   not	   expected	   to	   work	   alone	   without	   training,	   and	  
nobody	   expects	   steroids	   to	   induce	   muscle	   growth	   within	  
minutes	   and	   hours.	   	   Similarly,	   the	   antidepressant	   process	  
develops	  gradually	  and	  requires	  training	  and	  guidance.	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